Kornimate/medical-research-clean huggingface dataset:
effect of dotinurad in hyperuricemia with hypertension

Conditions: Hyperuricemia or Gout; Hypertension

Summary: the effect of dotinurad on cavi (cardio-ankle vascular index) will be compared with that of febuxostat in patients with hyperuricemia complicated by hypertension.

after determining eligibility of patients for whom consent is obtained, all patients who meet the eligibility criteria will be enrolled and randomized to one of two groups: dotinurad or febuxostat. in principle, a baseline (0-week) examination will be conducted within 70days after obtaining consent, followed by 24 weeks of observation and examination. during the observation period, no changes or additions to the dosage or administration of drugs other than the study drug will be made in principle, but changes or additions will be permitted under the overall clinical judgment of the physician in charge according to the medical conditions of the study participants.

Eligibility criteria:
inclusion criteria: 1. patients aged 20 years or older at the time of consent (regardless of gender) 2. patients with hyperuricemia with serum uric acid level \>7.0 mg/dl who have not received any urate lowering drug within 27 days prior to obtaining consent, or patients who were receiving urate lowering drugs at the time of obtaining consent but have been off the drugs for more than 27 days 3. hypertensive patients who meet the definition of hypertension in the latest hypertension treatment guidelines of the japanese society of hypertension and whose treatment for hypertension (with or without drug therapy) has not changed within 4 weeks prior to eligibility determination 4. patients who have given written consent to participate in this study exclusion criteria: 1. patients with unsettled gout after acute gouty arthritis 2. patients currently suffering from urinary tract stones 3. patients with known secondary hyperuricemia who have lesch-nyhan syndrome, hyperphosphoribosyl pyrophosphate synthase, congenital myogenic hyperuricemia, hematopoietic tumors (acute leukemia, malignant lymphoma, myeloproliferative disorders, myelodysplastic syndrome), solid tumors (breast cancer, seminoma, sarcoma, wilms' tumor, small cell lung cancer), non-neoplastic diseases (psoriasis vulgaris, secondary polycythemia vera, hemolytic anemia), tumor melting syndrome, rhabdomyolysis, hypothyroidism, polycystic kidney disease, lead poisoning/lead nephropathy, down syndrome, familial juvenile gout nephropathy, hyperlactatemia, or type 1 glycogenic disease 4. patients with hypertensive emergencies and urgency 5. patients with active malignancies 6. patients with severe hepatic dysfunction 7. patients with severe renal dysfunction with oliguria or anuria 8. pregnant, possibly pregnant, or lactating patients 9. patients with a history of hypersensitivity to the components of dotinurad and febuxostat 10. patients receiving mercaptopurine hydrate or azathioprine 11. other patients deemed inappropriate for this study by the investigator

Keywords: febuxostat dotinurad cavi arterial stiffness
effects of different recovery methods on lactic acid removal, flexibility, strength, and endurance

Conditions: Recovery Methods; Exercise Training

Summary: the aim of this study is to compare these three different recovery methods following a single bout high-intensity interval exercise program with each other in terms of blood lactate clearance, muscle flexibility, muscle strength and endurance.

it is very important to choose the most effective recovery method for the athletes in training for their next training/competition. the recovery period is very significant in terms of removal of blood lactate and body dynamics as soon as they return to their original state and achieve high performance. neither neuromuscular electrical stimulation, low-intensity aerobic exercise, self-massage with foam roller methods, which have been proven their effectiveness in the literature, have been compared with each other.

Eligibility criteria:
inclusion criteria: young, healthy adults aged 20-25 years. exclusion criteria: * clinical diagnosis of a cardiovascular disease. * clinical diagnosis of a metabolic disorder, orthopedic or neurological disease that would interfere with an exercise program, * clinical diagnosis of hemophili, * clinical diagnosis of thrombophlebitis or deep vein trombosis, * clinical diagnosis of peripheral arterial disease, * clinical diagnosis of venous insufficiency, * clinical diagnosis of anemia, * pregnancy.

Keywords: foam roller electrical stimulation low intensity aerobic training lactate removal
tax + cisplatin + 5 f/u vs cisplatin + 5 f/u in scchn

Conditions: Carcinoma, Squamous Cell

Summary: to describe the clinical response rate in two groups (docetaxel plus cisplatin plus 5-fu, versus cisplatin plus 5-fu) after 3 cycle of neoadjuvant chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven squamous cell carcinoma of the head and neck with locally advanced inoperable disease. * primary tumor sites eligible: oral cavity, oropharynx, hypopharynx , larynx or nasopharynx. * patients are required to have at least one (bi-or uni-dimensionally) measurable lesion. * who performance status 0 or 1. * adequate bone marrow, hepatic and renal functions. exclusion criteria: * pregnant and lactating women * previous chemotherapy * previous radiotherapy for h\&n * previous surgery for h\&n the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
topical cyclosporine for the treatment of dry eye in patients infected with the human immunodeficiency virus

Conditions: Dry Eye Syndromes; HIV Seropositivity

Summary: this study evaluates the use of topical cyclosporine 0.05% and sodium carboxymethylcellulose 0.5% for the treatment of dry eye disease in patients infected with the human immunodeficiency virus. twenty hiv-positive-patients were selected from the department of infectious diseases of the federal university of rio de janeiro hospital. dry eye diagnosis was based on a dry eye questionnaire (ocular surface disease index - osdi®), schirmer i test, break up time and 1% rose bengal staining of the ocular surface. the patients were divided into two groups with ten patients. group i received sodium carboxymethylcellulose 0.5% drops and group ii received sodium carboxymethylcellulose 0,5% drops and topical cyclosporine 0.05% for six months.


Eligibility criteria:
inclusion criteria: * hiv seropositivity * dry eye diagnosis exclusion criteria: * hepatitis b infection * hepatitis c infection * menopause * rheumatic diseases * contact lens wear * beta-blocker eye drops * blepharitis * use of medications associated with dry eye (diuretics, antidepressive agents, beta-blockers)

Keywords: dry eye syndromes keratoconjuntivitis sicca / drug therapy cyclosporine ophthalmic solutions hiv seropositivity
photodynamic therapy for permanent hair removal

Conditions: Hypertrichosis; Hirsutism

Summary: 24 test persons are treated with a dye suspension followed by a laser intervention. a decrease of hair density is expected.


Eligibility criteria:
inclusion criteria: * age 18-60 exclusion criteria: * anormal behavior * pregnancy * pathologic skin conditions * medication that my interfere with the study * allergy against the photosensitizer * lack of compliance * other reasons considered important by the investigator
effects of acute intermittent hypoxia on neuroplasticity in ms

Conditions: Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis, Secondary Progressive

Summary: this study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (ms) population. the breathing intervention, known as acute intermittent hypoxia (aih), involves breathing brief bouts of low levels of oxygen. research has found aih to be a safe and effective intervention resulting in increased ankle strength in people with ms. here, the study examines arm and hand function before and after aih. in order to better understand the brain and spinal cord response to aih, the investigators will measure muscle response, and signals sent from the brain to the arm muscles before and after aih.

while aih has shown potential in enhancing neuroplasticity in people with spinal cord injury (sci), it has yet to be studied extensively in ms. preliminary research in the ms population demonstrates that a single session of aih enhances motor output, increasing voluntary muscle strength by as much as 15-20% within 60 minutes. this study will explore potential mechanisms of aih in ms using measurements of arm function, as well as examination of corticospinal and spinal motoneuron excitability. over the past decade, studies have found that brief episodes of modest oxygen reduction (termed aih) can rapidly enhance neural plasticity in persons with incomplete sci. aih activates the serotonergic pathway, leading to increased activity of serotonin receptors and the synthesis of plasticity-related proteins. this plasticity is manifested by a rapid increase in voluntary muscle strength, emerging within 60-90 minutes, in both lower- and upper-limb muscles. the actions of aih appear to be biologically linked to systems designed to preserve breathing systems that are impaired by damage to the central nervous system (cns).

Eligibility criteria:
inclusion criteria: * diagnosis of relapsing-remitting ms according to the mcdonald criteria, over 5 years ago * relapse free for at least 6 months * expanded disability status scale (edss) ≤7 * index finger abduction strength \ 20 seconds in at least one hand * stable disease modifying therapies for at least 6 months * individuals taking dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening exclusion criteria: * another diagnosis (e.g., peripheral neuropathies or orthopedic) affecting upper limb function * mini-mental state examination (mmse) score \<24 * modified ashworth scale score \>3 on elbow joint * uncontrolled hypertension or hypotension (outside 140/90 and 85/55 mmhg) * history of epilepsy, chronic obstructive pulmonary disease, or sleep apnea * unstable medical conditions, ongoing upper limb therapy, or musculoskeletal pain * pregnancy as confirmed by urine test

Keywords: multiple sclerosis plasticity neuroplasticity motoneuron aih hypoxia acute intermittent hypoxia arm upper extremity
prospective evaluation of adjusted body weight dosing of acyclovir in obesity

Conditions: Obesity

Summary: patients receiving acyclovir as standard of care will be enrolled into this study. the currently recommended dosing strategy at our institution for obese patients is to receive intravenous acyclovir dosed per an adjusted body weight \[ibw + 0.4(tbw-ibw)\]. they will have blood drawn once prior to the first dose of acyclovir and 10 times thereafter, over a total time period of 12 hours. these patients will already be hospitalized for other reasons, and will not be required to make additional trips to the hospital. a total of approximately 4-5 tablespoons of blood will be drawn for this study. ten obese patients and 10 matched control (non-obese) patients will be enrolled.


Eligibility criteria:
inclusion criteria: * age ≥18 years of age * receiving intravenous acyclovir 5 mg/kg (tbw for normal weight patients and abw40 for obese patients) as part of their routine care * weight \> 190% of ideal body weight (ibw) for "obese" patients or weight 80-120% of ibw for matched control patients. exclusion criteria: * receipt of acyclovir or a pro-drug of acyclovir (valacyclovir, ganciclovir, valganciclovir, famciclovir) in the prior 24 hours * serum creatinine \>1.5 mg/dl * hypersensitivity to acyclovir * patients requiring ventilator support or vasopressors in the prior 24 hours * receipt of probenecid, mycophenolate, tenofovir, or zidovudine in the prior 7 days * significant anatomical deformities that influence body habitus (i.e. amputation) * prior inclusion in this study

Keywords: pharmacokinetics acyclovir
predictive value of ctdna for ned status in mcrc and its utility in guiding therapeutic intervention

Conditions: Metastatic Colorectal Cancer; No Evidence of Disease Status; ctDNA Monitoring

Summary: the goal of this clinical trial is to detect the prognostic value of longitudinal monitoring circulating tumor dna (ctdna) for no evidence of disease (ned) status in metastatic colorectal cancer (mcrc) patients and its utility in guiding therapeutic intervention. the main questions it aims to answer are: 1. whether ctdna monitoring could evaluate ned status ahead of normal radiologic monitoring. what about the concordance of evaluating ned status by ctdna monitoring compared with normal radiologic monitoring? 2. whether the patients with ctdna positive status could benefit from early therapeutic intervention. patients who receive any kinds of therapies with the aim of ned and are confirmed by clinical and radiologic examination will go through longitudinal ctdna monitoring. according to the results of ctdna monitoring, the patients will be divided into ctdna positive group and ctdna negative group. patients in ctdna positive group will receive individual therapeutic plan decided by the investigator. patients in ctdna negative group will receive regular examinations. when radiologic recurrences are confirmed, the patients will be re-evaluated for a second opportunity of radical resection.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years old. both male and female are eligible. 2. late stage metastatic colorectal adenocarcinoma diagnosed by histology or cytology. 3. with potential opportunity of achieving ned status (including liver metastasis, lung metastasis, solitary lymph node metastasis, ovarian metastasis or focal pelvic metastasis), regardless of neo-adjuvant therapy or transforming therapy. 4. patients who are intended for focal therapy, radical surgery, focal radiotherapy, radiofrequency ablation or interventional therapy (anhydrous alcohol injection or cryotherapy) 5. eastern cooperative oncology group (ecog) grade 1-2. 6. approve the informed consent. 7. available for tumor sample obtained by resection or aspiration. 8. available for peripheral blood collection (10ml per tube for 2 tubes) exclusion criteria: 1. cannot get histologic or cytologic diagnosis. 2. clinical tumor, node, and metastasis (ctnm) stage i-iii according to the american joint committee on cancer (ajcc), the 8th edition. 3. accompany with widespread metastasis and cannot achieve ned status by focal therapy, such as bone metastasis, peritoneum metastasis, diffuse liver or lung metastasis or malignant effusion, etc. 4. inadequate bone marrow reserve and organ function. 5. uncontrolled or severe systemic diseases, such as uncontrolled hyperplasia, severe infection, hepatitic b virus (hbv) infection, hepatitis c virus (hcv) infection, human immunodeficiency virus (hiv) infection, etc. 6. history of alcohol or drug abuse. 7. pregnant or lactating women. 8. cannot get tumor sample.
a six week, randomized, double-blind placebo-controlled, suvorexant augmentation study of antidepressant treatment of major depressive disorder with residual insomnia

Conditions: Depression; Major Depressive Disorder; MDD; Insomnia

Summary: depression with ongoing insomnia is a common clinical presentation with patients. clinical data suggests that patients with insomnia that receive concomitant treatment with a sleep aid experience a more robust antidepressant response along with a quicker response. the purpose of this clinical study is to compare the effectiveness of the fda-approved insomnia medication suvorexant, also known as belsomra®, as add-on treatment to an antidepressant to that of placebo plus antidepressant treatment in patients with depression and residual or ongoing insomnia.

many patients with depression suffer from residual insomnia. this study is a six week, randomized, double-blind, placebo-controlled, trial to study suvorexant augmentation of continuing antidepressant therapy against placebo with continuing antidepressant therapy. patient volunteers must be on a stable antidepressant treatment and will remain on this treatment for the duration of the study. patient volunteers that qualify and enroll in the clinical trial will either receive suvorexant 10 mg/day and may have it adjusted to a dose of either 15 mg or 20 mg/day. treatment is for a total of six weeks in addition to a clinical follow-up visit.

Eligibility criteria:
inclusion criteria: * provide written informed consent * diagnosis of depression (mdd) * currently on antidepressant * healthy and/or stable medically exclusion criteria: * unwilling to discontinue current use of sedative hypnotics/sleep aids/benzodiazepines or over the counter sleep aids/supplements * currently using other psychotropics other than antidepressants * at risk of self harm or a suicide attempt within the past 12 months * history or presence of psychotic disorders * known hypersensitivity to suvorexant * presence of any other sleep disorder other than residual insomnia of depression
rc48-adc combinatioed envolizumab in locally advanced or metastatic biliary tract cancer with positive her-2

Conditions: Biliary Tract Cancer

Summary: this study was a prospective, single-arm phase ii clinical trial to observe and evaluate the efficacy and safety of rc48-adc combined envafolimab in the first-line treatment of locally advanced or metastatic biliary tract cancer with positive her-2.


Eligibility criteria:
inclusion criteria: * 18 years; * ecog 0-1; * patients diagnosed by pathological or cytological diagnosis of locally advanced or metastatic biliary tract cancer (include intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder and ampullary carcinoma); * life expectancy of at least 3 months; * her2 ihc 2+ or 3+; * at least one measurable objective tumor lesion according to recist 1.1; * not received systemic chemotherapy in the past. patients who have completed adjuvant therapy or neoadjuvant therapy before the start of the chemotherapy regimen in this trial 6 months ago can be included in this trial. * satisfactory main organ function (laboratory test must meet the following criteria): hemoglobin (hgb) ≥90g/l, neutrophil count (anc) ≥1.5×109/l, platelet count (plt) ≥80×109/l, serum creatinine (cr) ≤1.5 upper normal limitation (unl), total bilirubin (tbil) ≤1.5 upper normal limitation (unl), alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 2.5 unl (for patients with liver metastasis, the ast/alt must be ≤5.0 unl), left ventricular ejection fraction (lvef) ≥ 50%; * subjects of childbearing potential must use an appropriate method of contraception during the study period and within 120 days after the end of the study, have a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects; exclusion criteria: * previously received drug therapy against pd-1/pd-l1 inhibitor and other antibody conjugate drug (such as t-dm1 and ds8201); * allergic to the active ingredients or excipients of the study drug; * biliary obstruction were excluded. unless blockage is treated locally, such as endoscopic stenting, percutaneous hepatic drainage, etc., total bilirubin is reduced below the upper limit of 1.5 unl; * a history of malignancies other than biliary tract malignancies (other than cured carcinoma in situ of the cervix or basal cell carcinoma of the skin and other malignancies cured for 5 years); * received major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of study treatment; or had a long-term unhealed wound or fracture; * unsuitable for the study or other chemotherapy determined by investigator.
atherosclerosis in rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Endothelial Dysfunction

Summary: the purpose of this study is to investigate the link between rheumatoid arthritis and cardiovascular disease by studying inflammation, joint disease, cholesterol abnormalities, and endothelial function.

in the general population, individuals with elevated inflammatory markers (e.g. c-reactive protein, crp) have increased cardiovascular disease. patients with ra have chronic elevations in crp and other inflammatory markers that are usually higher than the levels associated with increased cardiovascular risk in the general population. indeed, ra patients have accelerated disease of their blood vessels, and increased cardiovascular death not explained by traditional cardiac risk factors but associated with chronic inflammation. however, the mechanisms by which inflammation leads to cardiovascular disease are not well characterized in ra. moreover, current treatment strategies of ra largely target joint symptoms rather than inflammation, potentially leaving patients at increased risk for cardiovascular disease. studies of markers that increase the risk of heart disease in the full spectrum of ra are missing. we hypothesize that inflammatory markers will be more strongly associated with abnormalities in blood vessels in ra patients than any clinical measure of disease activity. this hypothesis will be tested with a cross-sectional study of patients in the ucsf ra cohort. aim 1 will characterize abnormal blood vessel changes across the spectrum of ra disease activity, specifically measuring ultrasound of the upper arm artery, markers of oxidative stress, and abnormalities in cholesterol proteins. aim 2 will identify factors associated with these changes across the spectrum of ra disease activity, specifically focusing on the association between inflammatory markers, cholesterol, and blood vessel abnormalities.

Eligibility criteria:
inclusion criteria: * diagnosis of ra by acr criteria * age 18-80 * enrolled in ucsf ra cohort already exclusion criteria: * diabetes (on meds or in medical history) * pregnant or lactating * renal failure (creatinine \> 2mg/dl or on dialysis) * history of mi or cad * history of ischemic cva * symptomatic pvd * current uncontrolled hypertension (blood pressure \> 160/100mmhg) * daily prednisone \> 10mg daily * current smoker * new bp med within 3 months * new statin within 3 months * change in ra meds: new or increase in prednisone within 1 month, new tnf inhibitor within 2 months, titration of methotrexate, leflunomide or sulfasalazine within 3 months.

Keywords: rheumatoid arthritis endothelial dysfunction lipoproteins inflammation oxidative stress arterial stiffness
determination of the characteristics of isometric gastric motility measurement in healthy volunteers

Conditions: Gastroparesis

Summary: there is a clear need for a novel method that can readily assess gastric motility in daily clinical practice. isometric determination of the stomach motility would avoid the use of a large flaccid balloon while still being affordable. the aim of this study was to determine the optimal balloon characteristics that enable to measure motility-induced pressure changes in healthy volunteers.


Eligibility criteria:
inclusion criteria: * they are between 18-60 years old. * male and female. * patients must provide witnessed written informed consent prior to any study procedures being performed. exclusion criteria: * they are older than 60 years old and younger than 18 years. * they are taking medication. * have severely decreased kidney function. * have severely decreased liver function. * have severe heart disease, for example a history of irregular heartbeats, angina or heart attack. * have severe lung disease. * have severe psychiatric illness or neurological illness. * have any gastrointestinal disease. * have any dyspeptic symptoms. * women that are pregnant or breastfeeding.

Keywords: stomach motility